Drug safety

Vitruvias recalls 30-mg thyroid tablets over excessive potency

The FDA says the nationwide, ongoing Class I recall covers Vitruvias’ 30-mg thyroid tablets because they are superpotent.

Reported by 2 outlets Wednesday, September 30, 2026

Pink tablets in a blister pack
Photo: CC0

The FDA classified Vitruvias Therapeutics’ recall of a lot of its levothyroxine-liothyronine Thyroid Tablets as Class I, its most serious recall classification, MedPage Today reported. The FDA’s recall record gives the reason as a superpotent drug.

The FDA record lists Thyroid Tablets, USP, 1/2 Grain (30 mg), with each tablet containing levothyroxine (T4) 19 mcg and liothyronine (T3) 4.5 mcg. The product is prescription-only and comes in bottles of 100 Tablets. The record says the products were distributed nationwide, the recall started 2026-08-21, and it was reported 2026-09-23. Its status is ongoing.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.